Neil Oronsky

636 total citations
21 papers, 493 citations indexed

About

Neil Oronsky is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Neil Oronsky has authored 21 papers receiving a total of 493 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Neil Oronsky's work include Epigenetics and DNA Methylation (7 papers), Histone Deacetylase Inhibitors Research (5 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Neil Oronsky is often cited by papers focused on Epigenetics and DNA Methylation (7 papers), Histone Deacetylase Inhibitors Research (5 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Neil Oronsky collaborates with scholars based in United States, Finland and South Africa. Neil Oronsky's co-authors include Bryan Oronsky, Michelle Lybeck, Arnold L. Oronsky, Scott Caroen, Jan Scicinski, Gary R. Fanger, Pedro Cabrales, Corey A. Carter, Tony R. Reid and Corey Carter and has published in prestigious journals such as Oncotarget, Journal of Cellular and Molecular Medicine and Frontiers in Oncology.

In The Last Decade

Neil Oronsky

21 papers receiving 488 citations

Peers

Neil Oronsky
Emman Shubbar Sweden
Moonkyoo Kong South Korea
Jiawen Dai China
Raghu Venkatramanamoorthy United States
Petros Giovanis Italy
Parul Gupta India
Kaibo Guo China
Daniel D. VonHoff United States
Nobuyasu Yoshimoto Japan
Zhiyi Liu China
Emman Shubbar Sweden
Neil Oronsky
Citations per year, relative to Neil Oronsky Neil Oronsky (= 1×) peers Emman Shubbar

Countries citing papers authored by Neil Oronsky

Since Specialization
Citations

This map shows the geographic impact of Neil Oronsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil Oronsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil Oronsky more than expected).

Fields of papers citing papers by Neil Oronsky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil Oronsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil Oronsky. The network helps show where Neil Oronsky may publish in the future.

Co-authorship network of co-authors of Neil Oronsky

This figure shows the co-authorship network connecting the top 25 collaborators of Neil Oronsky. A scholar is included among the top collaborators of Neil Oronsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil Oronsky. Neil Oronsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Oronsky, Bryan, Sharad Goyal, Michelle M. Kim, et al.. (2018). A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis. Translational Oncology. 11(3). 771–778. 75 indexed citations
2.
Oronsky, Bryan, Neil Oronsky, & Pedro Cabrales. (2018). Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RRx‐001. Journal of Cellular and Molecular Medicine. 22(10). 5076–5082. 7 indexed citations
3.
Brzezniak, Christina, Bryan Oronsky, Jane B. Trepel, et al.. (2017). RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor. Case Reports in Oncology. 10(1). 276–280. 6 indexed citations
4.
Oronsky, Bryan, Scott Caroen, Arnold L. Oronsky, et al.. (2017). Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management. Cancer Chemotherapy and Pharmacology. 80(5). 895–907. 72 indexed citations
5.
Oronsky, Bryan, Tony R. Reid, Pedro Cabrales, et al.. (2017). Navigating the “No Man's Land” of TKI-Failed EGFR-Mutated Non–Small Cell Lung Cancer (NSCLC): A Review. Neoplasia. 20(1). 92–98. 22 indexed citations
6.
Brzezniak, Christina, Patricia E. Hogan, Bryan Oronsky, et al.. (2017). A Case of Paraneoplastic Cushing Syndrome Presenting as Hyperglycemic Hyperosmolar Nonketotic Syndrome. Case Reports in Oncology. 10(1). 321–324. 3 indexed citations
7.
Cabrales, Pedro, Scott Caroen, Arnold L. Oronsky, et al.. (2017). The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury. Expert Review of Hematology. 10(6). 575–582. 13 indexed citations
8.
Fens, Marcel H.A.M., Pedro Cabrales, Jan Scicinski, et al.. (2016). Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation. Medical Oncology. 33(8). 85–85. 10 indexed citations
9.
Carter, Corey A., Regina M. Day, Patrick Richard, et al.. (2016). Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies. Oncotarget. 7(26). 40781–40791. 6 indexed citations
10.
Carter, Corey A., Bryan Oronsky, Scott Caroen, et al.. (2016). RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets. Case Reports in Oncology. 9(1). 171–176. 9 indexed citations
11.
Oronsky, Bryan, Jan Scicinski, Tony Reid, et al.. (2016). RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells.. PubMed. 21(116). 251–65. 22 indexed citations
12.
Oronsky, Bryan, Corey Carter, Arnold L. Oronsky, et al.. (2016). Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy. Oncotarget. 7(8). 9041–9045. 5 indexed citations
13.
Oronsky, Bryan, Jan Scicinski, Michelle M. Kim, et al.. (2016). Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents. Biomolecules. 6(3). 32–32. 10 indexed citations
14.
Oronsky, Bryan, Arnold L. Oronsky, Michelle Lybeck, et al.. (2015). Episensitization: Defying Time’s Arrow. Frontiers in Oncology. 5. 134–134. 32 indexed citations
15.
Oronsky, Bryan, Corey A. Carter, Tony R. Reid, et al.. (2015). Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man—PFS2: A Measure of Therapeutic Action-At-A-Distance. Neoplasia. 17(9). 716–722. 18 indexed citations
16.
Oronsky, Bryan, Corey A. Carter, Jan Scicinski, et al.. (2015). The War on Cancer: A Military Perspective. Frontiers in Oncology. 4. 387–387. 15 indexed citations
17.
Oronsky, Bryan, Gary R. Fanger, Neil Oronsky, Susan J. Knox, & Jan Scicinski. (2014). The Implications of Hyponitroxia in Cancer. Translational Oncology. 7(2). 167–173. 23 indexed citations
18.
Oronsky, Bryan, Neil Oronsky, Gary R. Fanger, et al.. (2014). Follow the ATP: Tumor Energy Production: A Perspective. Anti-Cancer Agents in Medicinal Chemistry. 14(9). 1187–1198. 66 indexed citations
19.
Oronsky, Bryan, Neil Oronsky, Jan Scicinski, et al.. (2014). Rewriting the Epigenetic Code for Tumor Resensitization: A Review. Translational Oncology. 7(5). 626–631. 31 indexed citations
20.
Oronsky, Bryan, Neil Oronsky, Susan J. Knox, Gary R. Fanger, & Jan Scicinski. (2014). Episensitization: Therapeutic Tumor Resensitization by Epigenetic Agents: A Review and Reassessment. Anti-Cancer Agents in Medicinal Chemistry. 14(8). 1121–1127. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Emman Shubbar Breakdown of academic impact, for papers by Moonkyoo Kong Breakdown of academic impact, for papers by Jiawen Dai Breakdown of academic impact, for papers by Raghu Venkatramanamoorthy Breakdown of academic impact, for papers by Petros Giovanis Breakdown of academic impact, for papers by Parul Gupta Breakdown of academic impact, for papers by Kaibo Guo Breakdown of academic impact, for papers by Daniel D. VonHoff Breakdown of academic impact, for papers by Nobuyasu Yoshimoto Breakdown of academic impact, for papers by Zhiyi Liu
Rankless by CCL
2026